Table 3.
AM Treatment Significantly Improved Treatment in Years 1, 2, and 5 Using Multivariate RMST Analysis Among All the Patients. Multivariate OS RMST regression for RMST difference (PM–AM) was performed at year 1–5, adjusting for covariates (as listed in the table) among all the patients. Regression coefficients with 95% CIs and P values were reported. A negative coefficient indicates worse survival of PM versus AM
| Terms | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | |
| intercept | 0.751 (0.546,0.957) | 8.16E−13 | 1.093(0.586,1.599) | 2.36E−05 | 1.322(0.47,2.174) | .0024 | 1.517(0.42,2.614) | .007 | 1.942(0.625,3.259) | .004 |
| TMZ timing (PM vs AM) | −0.086 (−0.155,−0.017) | .014 | −0.196 (−0.382,−0.01) | .039 | −0.263 (−0.547,0.021) | .0692 | −0.27 (−0.653,0.112) | .166 | −0.422 (−0.841,−0.004) | .048 |
| Sex (Male vs Female) | 0.02(−0.046,0.086) | .556 | −0.022 (−0.202,0.159) | .813 | −0.005 (−0.275,0.266) | .9735 | 0.093(−0.293,0.478) | .637 | −0.285 (−0.781,0.211) | .260 |
| age at TMZ start (continuous) | −0.002 (−0.005,0) | .090 | −0.008 (−0.015,−0.001) | .031 | −0.015 (−0.027,−0.003) | .0147 | −0.019(−0.035,−0.004) | .015 | −0.026 (−0.047,−0.005) | .015 |
| MGMT methylation (Yes vs No) | 0.156 (0.089,0.222) | 4.53E−06 | 0.626 (0.442,0.811) | 2.71E−11 | 0.912 (0.613,1.211) | 2.2E−09 | 1.274 (0.821,1.727) | 3.59E−08 | 1.603 (1.036,2.17) | 2.99E−08 |
| KPS (≥80 vs <80) | 0.059 (−0.017,0.134) | .129 | 0.176 (−0.042,0.393) | .114 | 0.269 (−0.083,0.622) | .1341 | 0.274 (−0.296,0.845) | .346 | 0.542 (0.086,0.998) | .020 |
| Extent of Surgical Resection (gross total resection vs subtotal/biopsy) | 0.126(0.058,0.194) | .000 | 0.269 (0.102,0.435) | .002 | 0.494(0.229,0.759) | .0003 | 0.652 (0.243,1.06) | .002 | 0.696 (0.207,1.186) | .005 |
| Baseline steroid Use (Yes vs No) | −0.052 (−0.121,0.016) | .135 | −0.059 (−0.243,0.125) | .530 | 0.019 (−0.297,0.335) | .9045 | 0.014 (−0.513,0.54) | .960 | 0.174 (−0.29,0.638) | .462 |
| Novocure Optune Use (Yes vs No) | −0.023 (−0.107,0.061) | .588 | 0.002 (−0.228,0.231) | .989 | −0.12 (−0.441,0.201) | .4643 | −0.214(−0.607,0.178) | .285 | −0.181 (−0.596,0.233) | .391 |
| DCVax Trial enrollment (Yes vs No) | 0.039(−0.053,0.131) | .405 | 0.24 (−0.011,0.491) | .060 | 0.309 (−0.146,0.764) | .1836 | 0.34(−0.289,0.97) | .289 | 0.416(−0.337,1.169) | .279 |
| other Trial enrollment (Yes. vs No) | 0.174(0.1,0.247) | 3.36E−06 | 0.39(0.217,0.564) | 1.03E−05 | 0.548(0.254,0.842) | .0003 | 0.448(−0.049,0.946) | .077 | 0.31(−0.142,0.763) | .179 |
Bold indicates significant P-values.